Multidrug resistance in cancer: role of ATP–dependent transporters
The DOI matches its Crossref record; 167 of the 168 references it cites were found in a registry or an index.
Abstract
Chemotherapeutics are the most effective treatment for metastatic tumours. However, the ability of cancer cells to become simultaneously resistant to different drugs--a trait known as multidrug resistance--remains a significant impediment to successful chemotherapy. Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents. Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A common mechanism of multidrug resistance consists in the overexpression of cancer drug–extruding ABC transporters in malignant cells (58).”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [58]
In the citing paper
“Prior exposure to taxanes during treatment of mCRPC can induce resistance mechanisms, including upregulation of efflux pumps or mutations in tubulin, that may compromise the efficacy of microtubule inhibitor-based ADCs246,247.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [247]
Citations
Cites
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“But why can some patients be cured by these approaches and others respond transiently or incompletely? Host and tumour genetic alterations, epigenetic changes and tumour environment all seem to contribute to the complex story of cancer drug resistanc”
BackgroundOverexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322 · cited 1×
“cgi?l=9429">ABCG2 — also known as MXR (mitoxantrone-resistance gene), BCRP (breast cancer resistance protein) or ABC-P (ABC transporter in placenta”
BackgroundNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · cited 1×
“Recent studies have emphasized the importance of the tumour vasculature and an appropriate pressure gradient for adequate drug delivery to the tumou”
BackgroundBIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059 · cited 1×
“asp?DrugCode=A%2D10166&DrugName=PACLITAXEL%2CSEMI%2DSYNTHETIC+INTRAVEN%2E&DrugType=1">paclitaxel”
Self-citationChen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Self-citationA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“The discovery of MRP1 stimulated a genomic search for homologues, leading to the discovery of eight additional members of the ABCC subfamily of transporters, of which six have been studied in some detai”
BackgroundThe Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
Research works printed but not linked: 3
- Solary, E. et al. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer 68, 1714–1719 (1991). · doi:10.1002/1097-0142(19911015)68:8<1714::aid-cncr2820680811>3.0.co;2-2
- Abraham, J. et al. A phase I study of the novel P-glycoprotein (PGP) antagonist, XR9576 in combination with vinorelbine. Proc. Am. Soc. Clin. Oncol. 20, 287 (2001).
- Fedeli, L. et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 64, 1805–1811 (1989). · doi:10.1002/1097-0142(19891101)64:9<1805::aid-cncr2820640908>3.0.co;2-d
Cited by
Items 201–300 of 1,041
Membrane Transporters and Channels
Huang, Y., Anderle, P., Bussey, K. J., Barbacioru, C., Shankavaram, U., Dai, Z., Reinhold, W. C., Papp, A., Weinstein, J. N., & Sadée, W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3884 · Cited by 285
“In particular, some ABC (ATP-binding cassette) transporters such as the multiple drug resistance transporter ABCB1 (multidrug resistance 1, P-glycoprotein) mediate energydependent efflux of drugs and thereby play major roles in the development of drug resistance ( 4 , 5). Electrochemical gradients established across m…”
BackgroundDomenech, M., Marrero-Berrios, I., Torres-Lugo, M., & Rinaldi, C. (2013) · ACS Nano · doi:10.1021/nn4007048 · Cited by 274
Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics
Calcagno, A. M., Salcido, C. D., Gillet, J.-P., Wu, C.-P., Fostel, J. M., Mumau, M. D., Gottesman, M. M., Varticovski, L., & Ambudkar, S. V. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq361 · Cited by 279
“Cancer that relapses after an initial response or that presents as chemotherapy-resistant disease is usually resistant to several chemically unrelated drugs in addition to the initial compound used in therapy (1).”
BackgroundSelf-citationBao, L., Hazari, S., Mehra, S., Kaushal, D., Moroz, K., & Dash, S. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.024 · Cited by 275
Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy
Kwan, P., & Brodie, M. J. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.31904.x · Cited by 281
“Much of the present knowledge about P-gp and other drug transporters has been gained in oncology because of their putative role in resistance in cancer chemotherapy (14,15).”
BackgroundNanomedicine in the diagnosis and therapy of neurodegenerative disorders
Kabanov, A. V., & Gendelman, H. E. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.014 · Cited by 277
“inhibitors of drug efflux transporters [289–291].”
An injectable nanoparticle generator enhances delivery of cancer therapeutics
Xu, R., Zhang, G., Mai, J., Deng, X., Segura-Ibarra, V., Wu, S., Shen, J., Liu, H., Hu, Z., Chen, L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3506 · Cited by 280
Zhang, Q., Wang, X., Li, P., Nguyen, K. T., Wang, X., Luo, Z., Zhang, H., Tan, N. S., & Zhao, Y. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201302988 · Cited by 276
Characterization of Oligomeric Human Half-ABC Transporter ATP-binding Cassette G2
Xu, J., Liu, Y., Yang, Y., Bates, S., & Zhang, J.-T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310785200 · Cited by 267
Self-citationPlasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3498 · Cited by 269
MacDiarmid, J. A., Amaro-Mugridge, N. B., Madrid-Weiss, J., Sedliarou, I., Wetzel, S., Kochar, K., Brahmbhatt, V. N., Phillips, L., Pattison, S. T., Petti, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1547 · Cited by 272
“, overexpression of the multi-drug resistance P-glycoprotein MDR”
BackgroundAgarwal, S., Sane, R., Gallardo, J. L., Ohlfest, J. R., & Elmquist, W. F. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167601 · Cited by 255
Shen, F., Chu, S., Bence, A. K., Bailey, B., Xue, X., Erickson, P. A., Montrose, M. H., Beck, W. T., & Erickson, L. C. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.127704 · Cited by 263
“Pgp expression is a component of the normal cellular defense system against xenobiotics (Gottesman et al., 2002).”
Background3D printed drug delivery and testing systems — a passing fad or the future?
Lim, S. H., Kathuria, H., Tan, J. J. Y., & Kang, L. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.05.006 · Cited by 252
Cell membrane coated nanocarriers - an efficient biomimetic platform for targeted therapy
Dash, P., Piras, A. M., & Dash, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.012 · Cited by 260
A DNA-Based Nanocarrier for Efficient Gene Delivery and Combined Cancer Therapy
Liu, J., Song, L., Liu, S., Jiang, Q., Liu, Q., Li, N., Wang, Z.-G., & Ding, B. (2018) · Nano Letters · doi:10.1021/acs.nanolett.7b04812 · Cited by 267
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Dong, J., Qin, Z., Zhang, W.-D., Cheng, G., Yehuda, A. G., Ashby, C. R., Chen, Z.-S., Cheng, X.-D., & Qin, J.-J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100681 · Cited by 255
Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
Murray, S., Briasoulis, E., Linardou, H., Bafaloukos, D., & Papadimitriou, C. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.02.011 · Cited by 261
Functional analysis of the ATP-binding cassette (ABC) transporter gene family of Tribolium castaneum
Broehan, G., Kroeger, T., Lorenzen, M., & Merzendorfer, H. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-6 · Cited by 249
“cells, and in insects they seem to be involved in insecticide resistance [36,37].”
BackgroundClassification Analysis of P-Glycoprotein Substrate Specificity
Didziapetris, R., Japertas, P., Avdeef, A., & Petrauskas, A. (2003) · Journal of Drug Targeting · doi:10.1080/10611860310001648248 · Cited by 253
“But MDR rever- sion and MDR-type resistance depend on many factors beyond the Pgp-mediated drug accumulation (Gottesman et al., 2002).”
BackgroundInfluentialCancer stem cells – important players in tumor therapy resistance
Colak, S., & Medema, J. P. (2014) · The FEBS Journal · doi:10.1111/febs.13023 · Cited by 248
Different strategies to overcome multidrug resistance in cancer
Saraswathy, M., & Gong, S. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.06.004 · Cited by 248
“However, in acquiredMDR, resistance to chemotherapy occurs during the course of the treatment or upon recurrence of the disease after successful chemotherapy (Baguley, 2010; Gottesman et al., 2002; Lage, 2008; Shaffer et al., 2012; Yague et al., 2007; Yuen and Sikic, 1994).”
BackgroundInfluentialThe Biology of Caveolae: Lessons from Caveolin Knockout Mice and Implications for Human Disease
Hnasko, R. (2003) · Molecular Interventions · doi:10.1124/mi.3.8.445 · Cited by 253
Evolution of acquired resistance to anti-cancer therapy
Foo, J., & Michor, F. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.02.025 · Cited by 254
“MDR may stem from changes that limit the accumulation of drugs within cells by decreasing uptake, enhancing efflux, or affecting membrane lipids (Liu et al., 2001), block apoptosis (Lowe et al., 1993), induce mechanisms that detoxify drugs and repair DNA damage (Synold et al., 2001), and modulate the cell cycle (Shah…”
BackgroundInfluentialSynonymous Mutations and Ribosome Stalling Can Lead to Altered Folding Pathways and Distinct Minima
Tsai, C.-J., Sauna, Z. E., Kimchi-Sarfaty, C., Ambudkar, S. V., Gottesman, M. M., & Nussinov, R. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.08.012 · Cited by 252
“Moreover, such changes can be measured using several wellestablished assays.(22)”
BackgroundSelf-citationDrug interactions with lipid membranes
Seddon, A. M., Casey, D., Law, R. V., Gee, A., Templer, R. H., & Ces, O. (2009) · Chemical Society Reviews · doi:10.1039/b813853m · Cited by 245
Manganese Oxide Nanoparticles As MRI Contrast Agents In Tumor Multimodal Imaging And Therapy
Cai, X., Zhu, Q., Zeng, Y., Zeng, Q., Chen, X., & Zhan, Y. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s218085 · Cited by 247
Altmann, K.-H., & Gertsch, J. (2007) · Nat. Prod. Rep. · doi:10.1039/b515619j · Cited by 248
Energy transduction and alternating access of the mammalian ABC transporter P-glycoprotein
Verhalen, B., Dastvan, R., Thangapandian, S., Peskova, Y., Koteiche, H. A., Nakamoto, R. K., Tajkhorshid, E., & Mchaourab, H. S. (2017) · Nature · doi:10.1038/nature21414 · Cited by 248
Natural Products for the Management and Prevention of Breast Cancer
Mitra, S., & Dash, R. (2018) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2018/8324696 · Cited by 244
“Therefore, understanding the molecular basis of MDR and developing medicines as well as treatment regimens to prevent drug resistance is an important priority [36].”
BackgroundVaults and the major vault protein: Novel roles in signal pathway regulation and immunity
Berger, W., Steiner, E., Grusch, M., Elbling, L., & Micksche, M. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8364-z · Cited by 253
Yu, H., Cui, Z., Yu, P., Guo, C., Feng, B., Jiang, T., Wang, S., Yin, Q., Zhong, D., Yang, X., et al. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201404484 · Cited by 253
Misra, S., Ghatak, S., & Toole, B. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500737200 · Cited by 245
Field, J. J., Kanakkanthara, A., & Miller, J. H. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.035 · Cited by 251
Dubikovskaya, E. A., Thorne, S. H., Pillow, T. H., Contag, C. H., & Wender, P. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805374105 · Cited by 249
“It arises from increased expression of membrane proteins that mediate unidirectional energy-dependent drug efflux, thereby intercepting and exporting the drug before it reaches its intracellular target (2).”
BackgroundRecent Trends in Targeted Anticancer Prodrug and Conjugate Design
Singh, Y., Palombo, M., & Sinko, P. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785132997 · Cited by 242
In situ self-assembly for cancer therapy and imaging
Kim, J., Lee, S., Kim, Y., Choi, M., Lee, I., Kim, E., Yoon, C. G., Pu, K., Kang, H., & Kim, J. S. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00589-3 · Cited by 238
Mallini, P., Lennard, T., Kirby, J., & Meeson, A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.09.008 · Cited by 240
“In fact, SP cells, a putative CSCs population, can be identified by their ability to efflux vital dyes through these transporters (Gottesman et al., 2002).”
BackgroundMolecular physiology of renal organic anion transporters
Sekine, T., Miyazaki, H., & Endou, H. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00439.2004 · Cited by 244
“The prototype of this family is P-gp, which extrudes various hydrophobic molecules, particularly antineoplastic compounds, such as vincristine, vinblastine, adriamycin, and daunorubicin, and confers multidrug resistance on cancer cells (20).”
BackgroundMahavorasirikul, W., Viyanant, V., Chaijaroenkul, W., Itharat, A., & Na-Bangchang, K. (2010) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-10-55 · Cited by 236
“Several genes involved in the apoptosis, detoxification and efflux processes have been reported to influence resistance to chemotherapeutic agents, for examples multidrug resistance protein (MDR1) and multidrug-resistance associated proteins (MRPs) [22], glutathione-S-transferase (GST) [23], dihydropyrimidine dehydrog…”
BackgroundSilent SNPs: Impact on Gene Function and Phenotype
Komar, A. A. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.8.1075 · Cited by 244
“However, in cancer patients, the function of P-gp can reduce the efficacy of chemotherapy treatments and, thus, P-gp represents an important target for drug-delivery purposes [13,14].”
BackgroundTargeted therapy for cancer stem cells: the patched pathway and ABC transporters
Lou, H., & Dean, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210200 · Cited by 239
“These efflux pumps are highly expressed in normal stem cells and provide protection from xenobiotic toxins (Gottesman et al., 2002).”
BackgroundThe Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy
Wu, C.-P., Hsieh, C.-H., & Wu, Y.-S. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200261n · Cited by 234
Platinum-Induced Neurotoxicity and Preventive Strategies: Past, Present, and Future
Avan, A., Postma, T. J., Ceresa, C., Avan, A., Cavaletti, G., Giovannetti, E., & Peters, G. J. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0044 · Cited by 232
Hegedűs, C., Özvegy‐Laczka, C., Apáti, Á., Magócsi, M., Német, K., Őrfi, L., Kéri, G., Katona, M., Takáts, Z., Váradi, A., et al. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00383.x · Cited by 228
Life history trade-offs in cancer evolution
Aktipis, C. A., Boddy, A. M., Gatenby, R. A., Brown, J. S., & Maley, C. C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3606 · Cited by 235
Single nucleotide polymorphisms modify the transporter activity of ABCG2
Morisaki, K., Robey, R. W., Özvegy-Laczka, C., Honjo, Y., Polgar, O., Steadman, K., Sarkadi, B., & Bates, S. E. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0931-x · Cited by 230
“ATP-binding cassette (ABC) transporters, such as P-glycoprotein (Pgp) and the multidrug resistanceassociated protein (MRP1), have been shown to confer resistance to a variety of chemotherapeutic agents by transporting drug substrates from cells in an energydependent manner [8, 15].”
BackgroundSelf-citationHu, F.-Q., Liu, L.-N., Du, Y.-Z., & Yuan, H. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.008 · Cited by 236
“P-gp expression impairs response to chemotherapy, and that expression levels increase as tumors become drug resistant [9].”
Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells
Huang, Y., & Sadée, W. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.07.032 · Cited by 230
In Situ Monitoring Apoptosis Process by a Self-Reporting Photosensitizer
Zhang, T., Li, Y., Zheng, Z., Ye, R., Zhang, Y., Kwok, R. T. K., Lam, J. W. Y., & Tang, B. Z. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b00636 · Cited by 235
Zhu, H., Chen, H., Zeng, X., Wang, Z., Zhang, X., Wu, Y., Gao, Y., Zhang, J., Liu, K., Liu, R., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.086 · Cited by 231
Phylogenetic analysis of fungal ABC transporters
Kovalchuk, A., & Driessen, A. J. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-177 · Cited by 228
“Undoubtedly, the most well-known members of this group are mammalian multidrug transporters, such as P-glycoprotein (Pgp) that is involved in drug resistance in cancer cells [46].”
BackgroundGold nanoparticles in combinatorial cancer therapy strategies
Beik, J., Khateri, M., Khosravi, Z., Kamrava, S. K., Kooranifar, S., Ghaznavi, H., & Shakeri-Zadeh, A. (2019) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2019.02.025 · Cited by 229
Saffron and natural carotenoids: Biochemical activities and anti-tumor effects
Bolhassani, A., Khavari, A., & Bathaie, S. Z. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.11.001 · Cited by 228
“A combination of cytotoxic drugs with non-toxic ABC transporter inhibitors (chemosensitizers) represents a new approach to overcome drug resistance [88,89].”
BackgroundQiu, L., Chen, T., Öçsoy, I., Yasun, E., Wu, C., Zhu, G., You, M., Han, D., Jiang, J., Yu, R., et al. (2015) · Nano Letters · doi:10.1021/nl503777s · Cited by 232
Chearwae, W., Anuchapreeda, S., Nandigama, K., Ambudkar, S. V., & Limtrakul, P. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.07.009 · Cited by 229
Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
Shukla, S., Ohnuma, S., & V. Ambudkar, S. (2011) · Current Drug Targets · doi:10.2174/138945011795378540 · Cited by 233
“P-gp pumps out many structurally unrelated anti-cancer drugs, such as vinca alkaloids (vinblastine, vincristine, vindesine, vinorelbine), anthracyclines (doxorubicin, daunorubicin) and taxanes (paclitaxel, docetaxel), suggesting the flexible nature of the substrate binding site of P-gp (10, 11).”
BackgroundThe role of ABC transporters in progression and clinical outcome of colorectal cancer
Hlavata, I., Mohelnikova-Duchonova, B., Vaclavikova, R., Liska, V., Pitule, P., Novak, P., Bruha, J., Vycital, O., Holubec, L., Treska, V., et al. (2012) · Mutagenesis · doi:10.1093/mutage/ger075 · Cited by 227
“Single-nucleotide polymorphisms (SNPs) in ABCB1 have been shown to influence its phenotype (expression, protein function and drug response) in context with numerous diseases [(11,18,19); supplementary Table VS, available at Mutagenesis Online].”
BackgroundInfluentialZhitomirsky, B., & Assaraf, Y. G. (2015) · Oncotarget · doi:10.18632/oncotarget.2732 · Cited by 225
“Numerous mechanisms of MDR have been described including decreased drug uptake, increased drug efflux via overexpression of MDR efflux transporters of the ATPbinding cassette (ABC) superfamily, quantitative and qualitative alterations in intracellular drug target proteins, as well as evasion of apoptosis [1, 3–8].”
BackgroundKuhnke, D., Jedlitschky, G., Grube, M., Krohn, M., Jucker, M., Mosyagin, I., Cascorbi, I., Walker, L. C., Kroemer, H. K., Warzok, R. W., et al. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00075.x · Cited by 226
“P-gp constitutes a major component of the BBB by limiting penetration of various exogenous agents (1, 8, 19).”
BackgroundMagnetically Triggered Dual Functional Nanoparticles for Resistance‐Free Apoptotic Hyperthermia
Yoo, D., Jeong, H., Noh, S., Lee, J., & Cheon, J. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201306557 · Cited by 230
Zhang, X., Wu, F., Liu, P., Gu, N., & Chen, Z. (2014) · Small · doi:10.1002/smll.201401658 · Cited by 229
Co-delivery of drugs and plasmid DNA for cancer therapy
Teo, P. Y., Cheng, W., Hedrick, J. L., & Yang, Y. Y. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.014 · Cited by 229
ABCG2: structure, function and role in drug response
Polgar, O., Robey, R. W., & Bates, S. E. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.1.1 · Cited by 224
“Overexpression of multi-drug resistance ATP-binding cassette (ABC) transporters is one of several ways by which cancer cells can become resistant to chemotherapy [1] .”
BackgroundSelf-citationCryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states
Manolaridis, I., Jackson, S. M., Taylor, N. M. I., Kowal, J., Stahlberg, H., & Locher, K. P. (2018) · Nature · doi:10.1038/s41586-018-0680-3 · Cited by 228
Colon cancer: Cancer stem cells markers, drug resistance and treatment
Kozovska, Z., Gabrisova, V., & Kucerova, L. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.10.019 · Cited by 228
O'Brien, F. E., Dinan, T. G., Griffin, B. T., & Cryan, J. F. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01557.x · Cited by 215
“Furthermore, ABC transporters have been implicated in resistance to pharmacotherapy, most notably in oncology, where the expression of these efflux pumps by cancer cells may confer resistance to chemotherapy with cytotoxic drugs in cancer patients (Gottesman et al., 2002; Szakacs et al., 2006).”
BackgroundpH-triggered intracellular release from actively targeting polymer micelles
Guo, X., Shi, C., Wang, J., Di, S., & Zhou, S. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.071 · Cited by 225
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy
Sparreboom, A., Danesi, R., Ando, Y., Chan, J., & Figg, W. D. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00005-0 · Cited by 226
“Inhibitors of ABC drug transporters represent a potential strategy for preventing the development of drug-resistant tumors (Gottesman et al., 2002).”
BackgroundRegulation of Multidrug Resistance in Cancer Cells by Hyaluronan
Misra, S., Ghatak, S., Zoltan-Jones, A., & Toole, B. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300173200 · Cited by 221
Pluronics and MDR reversal: an update
Alakhova, D. Y., & Kabanov, A. V. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500298q · Cited by 224
Amiri-Kordestani, L., Basseville, A., Kurdziel, K., Fojo, A. T., & Bates, S. E. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.02.002 · Cited by 219
Self-citationHyaluronan: A constitutive regulator of chemoresistance and malignancy in cancer cells
Toole, B. P., & Slomiany, M. G. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.009 · Cited by 220
“decreased uptake of drugs due to cell and tissue barriers, activation of repair and detoxification mechanisms, increased activities of antiapoptotic signaling pathways, or enhanced drug efflux via cell membrane transporters (59-62).”
BackgroundThe power of the pump: Mechanisms of action of P-glycoprotein (ABCB1)
Ambudkar, S. V., Kim, I.-W., & Sauna, Z. E. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.10.010 · Cited by 217
Mohammad, I. S., He, W., & Yin, L. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.038 · Cited by 218
Reversal of multidrug resistance in cancer cells by pyranocoumarins isolated from Radix Peucedani
Wu, J. Y.-C., Fong, W.-F., Zhang, J.-X., Leung, C.-H., Kwong, H.-L., Yang, M.-S., Li, D., & Cheung, H.-Y. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01946-0 · Cited by 221
Guo, D., Wu, C., Jiang, H., Li, Q., Wang, X., & Chen, B. (2008) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2008.07.009 · Cited by 218
Akhavan, O., Ghaderi, E., & Emamy, H. (2012) · Journal of Materials Chemistry · doi:10.1039/c2jm34330d · Cited by 220
Gillet, J.-P., Efferth, T., Steinbach, D., Hamels, J., de Longueville, F., Bertholet, V., & Remacle, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1978 · Cited by 222
“The ABCB1 (MDR1), ABCC1 (MRP1), and ABCG2 (MXR and BCRP) genes are the best known genes associated with MDR, and at least seven other ABC transporters are also capable of transporting drugs (2).”
BackgroundInfluentialNovel strategies to prevent the development of multidrug resistance (MDR) in cancer
Wang, J., Seebacher, N., Shi, H., Kan, Q., & Duan, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.19187 · Cited by 207
“Pgp is an ATPdependent drug-efflux pump, which exports a structurally and functionally diverse set of chemotherapy drugs from the inside of cancer cells to the outside, resulting in decreased intracellular drug accumulation [47].”
BackgroundCao, X., Fang, L., Gibbs, S., Huang, Y., Dai, Z., Wen, P., Zheng, X., Sadee, W., & Sun, D. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0291-9 · Cited by 221
“Strategies for reversing drug resistance have been explored based on over-expression of ABC transporters and oncogenic alterations of apoptotic and metabolism pathways [ 37 ].”
BackgroundAntibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
Dan, N., Setua, S., Kashyap, V., Khan, S., Jaggi, M., Yallapu, M., & Chauhan, S. (2018) · Pharmaceuticals · doi:10.3390/ph11020032 · Cited by 220
“However, the existence of abundant stromal/fibrosis (desmoplasia) in tumors, leads to inefficient drug delivery and emergence of drug resistance [3].”
Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters
Sajid, A., Rahman, H., & Ambudkar, S. V. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00612-3 · Cited by 201
“This work revealed that during the catalytic cycle, the conformational changes in intracellular helices 3 and 4 are critical for the communication between the drug-binding sites and NBDs 35 .”
BackgroundCo-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy
Qi, S.-S., Sun, J.-H., Yu, H.-H., & Yu, S.-Q. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1410256 · Cited by 218
Xu, L., Zou, C., Zhang, S., Chu, T. S. M., Zhang, Y., Chen, W., Zhao, C., Yang, L., Xu, Z., Dong, S., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01307-2 · Cited by 209
“In vitro studies have shown that CSC has high expression levels of drug transporters [117, 118] and anti-apoptotic proteins [119, 120], low oxygen free radical levels [121–123], strong ability to repair DNA damage [124, 125], and slow proliferation rate [121, 126].”
BackgroundDrug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes
Yardley, D. A. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/137414 · Cited by 216
“A mathematical model has been devised to describe the potency of combining chemotherapy and immunotherapy; however, it remains undefined whether most combinations are effective due to additive or synergistic cytotoxicity [64].”
MethodCancer stem cells and human malignant melanoma
Schatton, T., & Frank, M. H. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2007.00427.x · Cited by 210
“…cells, stemlike cancer cells have been found to be highly resistant to drugs and toxins, for example through the expression of MDR1 P-glycoprotein (ABCB1) or related ABC transporters, particularly during relapse (Dean et al., 2005; Frank et al., 2005; Gottesman et al., 2002; Wulf et al., 2001).”
BackgroundTumorigenesis of Chemotherapeutic Drug-Resistant Cancer Stem-Like Cells in Brain Glioma
Kang, M.-K., & Kang, S.-K. (2007) · Stem Cells and Development · doi:10.1089/scd.2007.0006 · Cited by 215
“Several studies have indicated that stem cells express a wide variety of transporters, including the members of ABC transporter family (23,24), and that these transporters are involved in drug efflux (25).”
Improving cancer therapy through the nanomaterials-assisted alleviation of hypoxia
Sahu, A., Kwon, I., & Tae, G. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119578 · Cited by 217
Tiwari, A. K., Sodani, K., Wang, S.-R., Kuang, Y.-H., Ashby, C. R., Chen, X., & Chen, Z.-S. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.002 · Cited by 209
Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates
Zhao, R. Y., Wilhelm, S. D., Audette, C., Jones, G., Leece, B. A., Lazar, A. C., Goldmacher, V. S., Singh, R., Kovtun, Y., Widdison, W. C., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2002958 · Cited by 215
Zhao, J., Cao, Y., Lei, Z., Yang, Z., Zhang, B., & Huang, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0283 · Cited by 211
“Although CD4 T cells may express ATP-binding cassette (ABC) transporters such as ABCB1 (35), which requires ATP for function (36), CY is a non–P-glycoprotein substrate drug (37).”
BackgroundRecurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma
Gunawardana, J., Chan, F. C., Telenius, A., Woolcock, B., Kridel, R., Tan, K. L., Ben-Neriah, S., Mottok, A., Lim, R. S., Boyle, M., et al. (2014) · Nature Genetics · doi:10.1038/ng.2900 · Cited by 206
PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy
Salaroglio, I. C., Panada, E., Moiso, E., Buondonno, I., Provero, P., Rubinstein, M., Kopecka, J., & Riganti, C. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0657-0 · Cited by 206
“therapy-agents, determining multidrug resistance (MDR) [8].”
Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?
Szumilak, M., Wiktorowska-Owczarek, A., & Stanczak, A. (2021) · Molecules · doi:10.3390/molecules26092601 · Cited by 197
“They are capable of extruding a wide range of anticancer drugs, thus reducing their intracellular concentration and, subsequently, facilitating the development of resistance [76].”
BackgroundMolecular Pharmacology of ABCG2 and Its Role in Chemoresistance
Stacy, A. E., Jansson, P. J., & Richardson, D. R. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.088609 · Cited by 210
“…that P-gp can transport a range of hydrophobic chemotherapeutics such as anthracyclines, taxanes, etoposide, and mitoxantrone (Juliano and Ling, 1976; Gottesman et al., 2002) and was originally thought to be solely responsible for the MDR phenotype (Juliano and Ling, 1976; Gottesman et al., 2002).”
BackgroundThe role of aldehyde dehydrogenase (ALDH) in cancer drug resistance
Januchowski, R., Wojtowicz, K., & Zabel, M. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.04.005 · Cited by 202
Yan, D., Talbot, A., Nourmohammadi, N., Sherman, J. H., Cheng, X., & Keidar, M. (2015) · Biointerphases · doi:10.1116/1.4938020 · Cited by 206
Toxicology of Cadmium and Its Damage to Mammalian Organs
Thévenod, F., & Lee, W.-K. (2013) · Metal Ions in Life Sciences · doi:10.1007/978-94-007-5179-8_14 · Cited by 207
Hyaluronan Regulates Cell Behavior: A Potential Niche Matrix for Stem Cells
Solis, M. A., Chen, Y.-H., Wong, T. Y., Bittencourt, V. Z., Lin, Y.-C., & Huang, L. L. H. (2012) · Biochemistry Research International · doi:10.1155/2012/346972 · Cited by 206
““Classic multidrug” resistance (MDR) is caused by increased drug export through ATP-dependent efflux pumps, such as multidrug-resistance proteins (MRPs), and other members of the ATP-binding cassette (ABC) transporter families [69].”
Background
Metadata
- Authors
- Gottesman, M. M., Fojo, T., & Bates, S. E.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Fojo, Tito
- Venue
- Nature Reviews Cancer
- Published
- 2002-01-01
- Volume
- 2
- Issue
- 1
- Pages
- 48-58
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2006434892
- Cited by
- 5,536
- References
- 168
- Citations by year
- 2026: 144 · 2025: 173 · 2024: 183 · 2023: 228 · 2022: 231 · 2021: 257 · 2020: 305 · 2019: 281 · 2018: 318 · 2017: 322 · 2016: 329 · 2015: 333 · 2014: 326 · 2013: 296 · 2012: 274
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Keywords
- multidrug resistance, drug efflux pumps, chemoresistance, cancer chemotherapy, drug resistance mechanisms, metastatic cancer
- MeSH terms
- Adenosine Triphosphate, Antineoplastic Agents, Breast Neoplasms, Female, Forecasting, Multigene Family, Humans, Leukemia, Neoplasm Proteins, Neoplasms, Organ Specificity, Permeability, Structure-Activity Relationship, Drug Design, Xenobiotics, Biomarkers, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, ATP-Binding Cassette, Sub-Family C Proteins, Multidrug Resistance-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.